NRC Health (NRC)
Nasdaq · Services-Commercial Physical & Biological Research · Services · CIK 70487 · fiscal year ends in Dec
Closing price $23.52 on 29 Oct 2026; 52-week range $12.03 to $23.52.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $140.0M
- Revenue growth
- -0.2%
- Net income, last twelve months
- $5.6M
- Earnings per share
- $0.25
- Operating margin
- 10.5%
- Net margin
- 4.0%
- Free cash flow
- $21.6M
- Return on equity
- 85.7%
- Market value
- $520.7M
- Price to earnings
- 94.1x
- Dividend yield
- 2.6%
- Cash
- $3.3M
- Debt
- $90.0M
- Debt to equity
- 13.75
- Shares outstanding
- 22.1M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $137.4M | $22.6M | $11.3M | $50.00 | $15.7M | 10-K filed 5 Mar 2026 |
| FY2024 | 31 Dec 2024 | $143.1M | $35.2M | $24.8M | $1.04 | $19.2M | 10-K filed 17 Mar 2025 |
| FY2023 | 31 Dec 2023 | $148.6M | $40.0M | $31.0M | $1.25 | $22.3M | 10-K filed 27 Feb 2024 |
| FY2022 | 31 Dec 2022 | $151.6M | $46.5M | $31.8M | $1.27 | $26.4M | 10-K filed 3 Mar 2023 |
| FY2021 | 31 Dec 2021 | $148.0M | $50.3M | $37.4M | $1.46 | $40.8M | 10-K filed 4 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $35.4M | -$3.3M | -$0.15 |
| Q1 FY2026 | 31 Mar 2026 | $34.8M | $3.2M | $0.14 |
| Q4 FY2025 | 31 Dec 2025 | $35.2M | $1.7M | $0.08 |
| Q3 FY2025 | 30 Sep 2025 | $34.6M | $4.0M | $0.18 |
| Q2 FY2025 | 30 Jun 2025 | $34.0M | -$106.0K | -$0.01 |
| Q1 FY2025 | 31 Mar 2025 | $33.6M | $5.8M | $0.25 |
| Q4 FY2024 | 31 Dec 2024 | $36.9M | $6.6M | $0.28 |
| Q3 FY2024 | 30 Sep 2024 | $35.8M | $5.7M | $0.24 |
Company events
The newest 8-K filings of 151 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 27 Oct 2026 | 8-K | Results | 2.02, 9.01 |
| 19 Oct 2026 | 8-K | Leadership change | 5.02 |
| 11 Aug 2026 | 8-K | Leadership change | 5.02 |
| 28 Jul 2026 | 8-K | Results | 2.02, 9.01 |
| 29 Jun 2026 | 8-K | Shareholder vote, Bylaws or fiscal year change | 5.03, 5.07, 9.01 |
| 28 Apr 2026 | 8-K | Leadership change | 5.02 |
| 28 Apr 2026 | 8-K | Results | 2.02, 9.01 |
| 20 Apr 2026 | 8-K | Leadership change, Bylaws or fiscal year change | 5.02, 5.03, 9.01 |
| 5 Mar 2026 | 8-K | Investor update | 7.01, 9.01 |
| 3 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 27 Oct 2025 | 8-K | Results | 2.02, 9.01 |
| 28 Aug 2025 | 8-K | Leadership change | 5.02, 9.01 |
Every filing
The newest filings with the SEC of 423 held.
| Filed | Form | Period |
|---|---|---|
| 27 Oct 2026 | 8-K | 27 Oct 2026 |
| 19 Oct 2026 | 8-K | 14 Oct 2026 |
| 11 Aug 2026 | 8-K | 7 Aug 2026 |
| 4 Aug 2026 | 10-Q | 30 Jun 2026 |
| 28 Jul 2026 | 8-K | 28 Jul 2026 |
| 29 Jun 2026 | 8-K | 23 Jun 2026 |
| 8 May 2026 | ARS | 31 Dec 2025 |
| 8 May 2026 | DEFA14A | – |
| 8 May 2026 | DEF 14A | 23 Jun 2026 |
| 6 May 2026 | 10-Q | 31 Mar 2026 |
| 28 Apr 2026 | PRE 14A | 23 Jun 2026 |
| 28 Apr 2026 | 10-K/A | 31 Dec 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 17 Feb 2026 | Harrison Shane R, EVP & Chief Financial Officer | Purchase | 8,000 | $12.27 | $98.2K | 8,000 | 19 Feb 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 13 Aug 2026 | Kayne Anderson Rudnick Investment Management, LLC | 13G amended | 9% | 2.0M |
| 12 Jun 2026 | Common Property Trust | 13D amended | 45.7% | 10.3M |
| 27 Mar 2026 | Common Property Trust | 13D amended | 46.5% | 10.6M |
| 13 Feb 2026 | Kayne Anderson Rudnick Investment Management, LLC | 13G amended | 11.7% | 2.7M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 725.6K | +5.83% | 8.07 |
| 30 Sep 2026 | 685.6K | +0.04% | 4.98 |
| 15 Sep 2026 | 685.4K | +7.65% | 5.93 |
| 31 Aug 2026 | 636.7K | +14.86% | 5.54 |
| 14 Aug 2026 | 554.3K | +7.6% | 4.42 |
| 31 Jul 2026 | 515.2K | -1.09% | 5.37 |
| 15 Jul 2026 | 520.8K | +11.13% | 6.16 |
| 30 Jun 2026 | 468.7K | +12.16% | 3.46 |
Funds that hold it
From each fund's latest Form 13F.
134 funds held it at 30 Jun 2026: 58 added and 39 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Kayne Anderson Rudnick Investment Management LLC | 2,030,492 | $43.8M | -605,863 |
| BlackRock, Inc. | 1,061,355 | $22.9M | +85,500 |
| Morgan Stanley | 859,269 | $18.5M | -142,611 |
| Vanguard Capital Management LLC | 666,554 | $14.4M | +3,717 |
| Dimensional Fund Advisors LP | 491,228 | $10.6M | +1,488 |
| Willis Investment Counsel | 434,785 | $9.4M | +210,147 |
| Geode Capital Management, LLC | 420,056 | $9.1M | +26,209 |
| QV Investors Inc. | 372,503 | $8.0M | -8,807 |
| Farmers & Merchants Investments Inc. | 330,649 | $7.1M | +330,549 |
| Renaissance Technologies LLC | 325,384 | $7.0M | -15,400 |
Peers
Companies in the same industry.
- IQVIA Holdings Inc. (IQV): revenue $17.3B, market value $45.3B
- Incyte Corp. (INCY): revenue $6.0B, market value $23.8B
- Medpace Holdings, Inc. (MEDP): revenue $2.8B, market value $18.9B
- Charles River Laboratories International, Inc. (CRL): revenue $4.0B, market value $18.0B
- ICON plc (ICLR): revenue $8.3B, market value $16.5B
- Absci Corp. (ABSI): revenue $1.6M, market value $2.1B
- OmniAb, Inc. (OABI): revenue $40.2M, market value $762.8M